Lecture Series

Meeting Information From the Group

For Closed Captions, start the video and click CC at the bottom.


The GSA KAER Toolkit for Primary Care Teams

Karen K. Tracy, BS and Jennifer L. Pettis, MS

Karen K. Tracy, BS
Karen K. Tracy, BS
Jennifer Pettis, MS
Jennifer Pettis, MS

Sequential Administration of DIGItal Testing in the Primary Care Setting to Screen for Cognitive Impairment Followed by Blood Based Biomarkers to Assist with Timely Detection and Accurate Diagnosis of ALzheimer's Disease at Indiana University (IU) and IU Health (IUH)

Nicole Fowler, PhD 


Considering a Framework for Return of Individual Research Results

Barbara E. Bierer, MD


Blood Tests for Alzheimer's Disease

Thomas Karikari, PhD


Considerations Regarding a Diagnosis of AD Based on Biomarkers

Jetske van der Schaar, MS


FDA Market Authorization of the Lumipulse® β-Amyloid Ratio (1-42/1-40) Test

Rianne Esquivel, PhD


Overview: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Plans For ADNI4 Improving Generalizability by Increasing Diversity

Michael Weiner, MD


Development of Algorithm to Calculate 5 Year Absolute Risk of AD

Sarah Hartz, MD, PhD and Jessica Mozersky, PhD


Sharing Biomarker Results with Cognitively Healthy Research Participants

Lindsay Clark, PhD


Update on Status of Blood-Based Markers for Alzheimer's Disease: 

Readiness for Clinical Use 

Michelle M. Mielke, PhD


Biofluid Biomarkers of Neuropsychiatric Symptoms in Dementia with 

Lewy Bodies & Alzheimer's Disease

Fabricio Oliveira, MD, PhD 


Dementia in the Borderlands

Gladys Maestre, MD, PhD


Aducanumab: Where do we go from here?

Joshua Grill, PhD


The Next Steps Towards Precision Medicine in Parkinson's Disease

Ron Alcalay, MD


Communicating 5 Year Risk of AD Dementia Based on Multiple Research Results to a Longitudinal Cohort of Healthy Older Adults

Jessica Mozersky, PhD


Overcoming Stigma

Rev. Dr. Cynthia Huling Hummel


Results from the Study of Knowledge and Reactions to Amyloid Testing (SOKRATES)

Emily A. Largent, JD, PhD 


The First Blood Test for Alzheimer Disease is Now Available for Clinical Use

Suzanne Schindler, MD


Utilization of Cerebrospinal Fluid Biomarkers for the Detection 

of Alzheimer's Disease in Mild Cognitive Impairment 

and Subjective Cognitive Decline in Routine Clinical Care in Germany

Anja Schneider, MD


Deepening Stakeholder Engagement through attendance of 

a virtual Scientific Conference

Sarah Walter, MSc  


Asian Cohort for Alzheimer's Disease Study

Li-San Wang, PhD 


 Legal Protections and Vulnerabilities from Genetic and Biomarkers

Jalayne Arias, JD


Return of Genomic Results in All of Us

Robert C. Green, MD



Ethics in the European Prevention of Alzheimer's Dementia (EPAD) project

Richard Milne, PhD 


MRI Face Recognition and De-Identification

Christopher Schwartz, PhD 


COVID-19 Issues

Robyn S. Shapiro, JD


Effects of Advances in Biomarker-Based Diagnosis and Disease-Modifying Treatment on Alzheimer's Disease Stigma 

Shana D. Stites, PsyD


VISN 17 Center of Excellence for Research on Returning War Veterans

Laura Zambrano-Vazquez, PhD


Upcoming Speakers

December 15 Charlotte Teunissen